The historical rank and industry rank for Prostatype Genomics AB's Net Margin % or its related term are showing as below:
OSTO:PROGEN'
s Net Margin % Range Over the Past 10 Years
Min: -156300 Med: -7492.09 Max: -3055.68
Current: -7492.09
OSTO:PROGEN's Net Margin % is ranked worse than 97.04% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.43
vs OSTO:PROGEN: -7492.09
Prostatype Genomics AB (OSTO:PROGEN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Prostatype Genomics AB Net Margin % Related Terms
Prostatype Genomics AB Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a Net Margin % of -5,914.66% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #197 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 97%.
Is Prostatype Genomics AB's Net Margin % too high?
Prostatype Genomics AB's current Net Margin % is -5,914.66%. Based on the distribution chart, Prostatype Genomics AB ranks #197 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #197 out of 203 companies for Net Margin %. This places Prostatype Genomics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Net Margin % is -5,914.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current Net Margin % is -5,914.66%. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Net Margin % is -5,914.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Net Margin %: -5,914.66%
GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score
Get the complete analysis for OSTO:PROGEN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
